ADJUVANT COMPARISON AND CHARACTERIZATION

佐剂比较和表征

• 批准号: 10703849
• 负责人: BALI PULENDRAN
• 金额: $ 329.97万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10703849
• 关键词: Adjuvant; COVID-19 vaccine; Data Analyses; Fingerprint; Goals; Human; Immune; Immunologics; Mus; Organoids; Side; Tissues; Tonsil; Vaccine Antigen; Work; adaptive immune response; clinically relevant; data management; programs

The goal of the Adjuvant Comparison and Characterization (ACC) program is to support side-by-side comparison of adjuvants in combination with clinically relevant vaccine/antigen platforms, and to establish both systemic and tissue-specific immunological profiles (“immune fingerprints”) of adjuvants that work through different mechanisms in the context of Sars-CoV-2 vaccines.

佐剂比较和表征(ACC)计划的目标是支持佐剂与临床相关疫苗/抗原平台相结合的并列比较，并建立在SARS-CoV-2疫苗背景下通过不同机制发挥作用的佐剂的系统和组织特异性免疫学特征(“免疫指纹”)。